The Real Disadvantages of Mounjaro — and What They Actually Mean for You

The biggest misconception: 'the side effects are just mild nausea for a few days'

A question our prescribers hear most weeks runs roughly like this: 'I've read it's just a bit of nausea at first, is that right?' The short answer is that for many people the gastrointestinal effects are manageable and do ease, but the full picture is worth stating plainly. According to the NHS tirzepatide medicines page, common side effects include nausea, vomiting, diarrhoea, constipation, acid reflux, burping, fatigue, headache, dizziness and injection-site reactions. That's a broader list than 'a bit of nausea'.

These effects tend to be most pronounced in the first few weeks and again after each dose increase. For some patients they pass quickly; for others they are genuinely disruptive to daily life. Eating smaller portions, avoiding high-fat meals and staying well hydrated helps most people get through the adjustment. But it is reasonable to weigh this honestly rather than assume the best-case version.

There are rarer but more serious concerns too. The MHRA issued a Drug Safety Update in January 2026 highlighting acute pancreatitis as an infrequent but potentially serious risk with GLP-1 medicines: severe, persistent stomach pain that spreads to the back (with or without vomiting) requires urgent medical attention, not a wait-and-see approach. Gallbladder problems are also on the watch list. These risks don't make Mounjaro unsuitable for most people, but they do make clinical oversight non-negotiable. You can report any suspected side effect through the MHRA's Yellow Card scheme, which also accepts reports about suspect sellers.

The practical disadvantages: injections, storage and supply

Mounjaro is a once-weekly subcutaneous injection delivered by a pre-filled KwikPen. For patients who have never self-injected, this is a significant practical step, one that most people manage well after the first few attempts, but that should still be acknowledged as a disadvantage for anyone needle-averse. The injection goes into the abdomen, thigh or upper arm; rotating sites each week reduces localised reactions.

Storage is another constraint. Mounjaro must be kept refrigerated at 2–8°C. If you travel frequently or your fridge situation is unreliable, planning ahead matters. The pen's room-temperature tolerance window is limited, the exact duration is detailed in the Patient Information Leaflet, and you should follow that rather than any general online guidance, because the window differs from what circulates on forums.

Supply has also been a real-world disadvantage. UK shortages have affected availability at various points, as covered in detail on the Mounjaro shortages page. Anyone who has found a dose unavailable mid-treatment knows the disruption this causes. If you are wondering whether you can still get Mounjaro given ongoing supply pressures, it is worth reading up on the current situation before you start rather than discovering it at a critical point in your titration.

Titration itself is gradual by design. Treatment begins at 2.5mg (a dose whose job is to let your system adjust, not to produce significant weight loss) and increases in steps, typically every four weeks, toward the therapeutic range. This means results build slowly, which is clinically sound but can feel frustrating. You can read more about how the stages work on the Mounjaro stages page.

Cost, eligibility and what the NHS does (and doesn't) cover

Cost is a legitimate disadvantage for private patients. Eli Lilly raised Mounjaro's UK list price substantially from September 2025 (the highest-dose pen's list price moved from around £122 to around £330) and typical private prices across providers have ranged roughly £149–£375 per month by dose since then, as widely reported. If you are considering the full licensed course, this is a material ongoing expense. A detailed look at what drives those figures is available on the Mounjaro price comparison page.

NHS access exists but is strictly rationed. NICE's appraisal of tirzepatide (TA1026) recommends it for adults with a BMI of 35 or above plus at least one qualifying weight-related condition, through a phased rollout that expanded to a second cohort in June 2026. Lower BMI thresholds apply for some ethnic backgrounds under UK guidance. Many people who would benefit clinically do not yet meet the NHS criteria, or face long waits even when they do. That gap is the practical reality that drives most enquiries to private services.

On BMI alone, neither a qualifying number nor a weight-related condition guarantees approval. A prescriber reviews the whole picture, including medicines that interact with Mounjaro, conditions that contraindicate it, and whether the patient is pregnant, breastfeeding or trying to conceive (not recommended in any of those situations). People under 18 are not within the licensed population. For a broader look at how results vary across the population, the Mounjaro weight-loss percentage page puts the trial data in context without overstating it.

The Black Triangle status and what we still don't know

Mounjaro carries a Black Triangle (▼) designation in the UK, meaning the MHRA requires enhanced reporting of side effects because long-term data is still accumulating. This is standard for newer medicines and does not indicate a known problem, but it is honest to say that a medicine approved in 2023 has a shorter safety record than one approved in 2003. For patients planning years of treatment, that is worth factoring in.

Muscle loss during rapid weight reduction is a related concern raised in clinical discussion. Some data suggests GLP-1 and dual-agonist medicines can reduce lean mass alongside fat mass if protein intake and resistance activity are not maintained. This is manageable (the clinical advice is to prioritise protein and strength training) but it is a disadvantage that a purely weight-focused view of the medicine tends to miss. If you want to understand the full clinical and scientific picture of how tirzepatide works, the tirzepatide overview page covers the mechanism in depth.

None of this is a reason to rule Mounjaro out. For many patients the benefit-to-risk balance is clearly favourable, and the trial evidence for weight reduction is substantial. But the drawbacks are real, and a good prescriber will discuss them with you rather than gloss over them. If you have read this page and want to talk through whether Mounjaro is appropriate for your situation, you can speak to our prescribers through a free consultation, reviewed the same day by a GPhC-registered Independent Prescriber, not by an algorithm.